Literature DB >> 10708161

Altered plasma cytokines and total glutathione levels in parenterally fed critically ill trauma patients with adjuvant recombinant human growth hormone (rhGH) therapy.

M Jeevanandam1, C K Begay, L M Shahbazian, S R Petersen.   

Abstract

OBJECTIVES: Glutathione (GSH) is a potent endogenous antioxidant that serves as one of the body's most important defenses against oxygen metabolites. Plasma levels of GSH are maintained primarily by a balance between secretion from the liver and degradation in the kidney. The ability to maintain and enhance tissue GSH may be of particular importance in controlling cytokine production in response to a stimulus like injury. The interaction after severe trauma between GSH and cytokines, tumor necrosis factor (TNF) -alpha, and interleukin (IL)-6, are not known. The purpose of the study was to investigate the levels of plasma GSH and cytokines TNF-alpha and IL-6 in adult patients admitted to the intensive care unit of our level I trauma center who were treated with recombinant human growth hormone (rhGH) for > or =7 days.
DESIGN: Prospective, randomized, controlled trial.
SETTING: Trauma intensive care unit. PATIENTS: Twenty-eight patients with multiple injuries and 14 normal postabsorptive controls.
INTERVENTIONS: From 48-60 hrs after injury, when resuscitation was complete, a stable hemodynamic status was achieved and the patients were receiving maintenance fluid without nitrogen or calories, a blood sample was drawn for basal, plasma GSH, TNF-alpha, and IL-6 measurement. Intravenous feeding was then started and continued for 7 days. The patients were randomized to receive or not to receive daily intramuscular doses of recombinant human growth hormone (0.15 mg rhGH/kg/day). Daily morning plasma was obtained for analysis of GSH, TNF-alpha, and IL-6 levels.
RESULTS: In the early catabolic "flow phase" of severe injury, the plasma levels of GSH were not altered but plasma TNF-alpha and IL-6 levels were increased significantly, compared with uninjured controls. Seven days of total parenteral nutrition alone enhanced plasma GSH levels (76%), but no change in TNF-alpha was observed. Supplementation with rhGH enhanced GSH (180%), and TNF (65%) with no changes in IL-6 levels. There is a significant linear relationship between plasma GSH and TNF-alpha levels in our rhGH-supplemented trauma patients.
CONCLUSION: Modification of plasma GSH and TNF-alpha levels by adequate nutritional support with adjuvant rhGH during the postinjury period demonstrates the beneficial role of GSH in enhancing antioxidant defenses.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10708161     DOI: 10.1097/00003246-200002000-00006

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  5 in total

Review 1.  Nutritional support in the critically ill child.

Authors:  Parvathi U Iyer
Journal:  Indian J Pediatr       Date:  2002-05       Impact factor: 1.967

2.  Extracellular conversion of adiponectin hexamers into trimers.

Authors:  Jeong-A Kim; Martha Nuñez; David B Briggs; Bethany L Laskowski; Jimmy J Chhun; Joseph K Eleid; Michael J Quon; Tsu-Shuen Tsao
Journal:  Biosci Rep       Date:  2012-12       Impact factor: 3.840

3.  Dissecting the role of glutathione biosynthesis in Plasmodium falciparum.

Authors:  Eva-Maria Patzewitz; Eleanor H Wong; Sylke Müller
Journal:  Mol Microbiol       Date:  2011-12-11       Impact factor: 3.501

4.  Oxidative stress is increased in critically ill patients according to antioxidant vitamins intake, independent of severity: a cohort study.

Authors:  Jimena Abilés; Antonio Pérez de la Cruz; José Castaño; Manuel Rodríguez-Elvira; Eduardo Aguayo; Rosario Moreno-Torres; Juan Llopis; Pilar Aranda; Sandro Argüelles; Antonio Ayala; Alberto Machado de la Quintana; Elena Maria Planells
Journal:  Crit Care       Date:  2006       Impact factor: 9.097

5.  The Relationship Between Vitamin E Plasma and BAL Concentrations, SOD Activity and Ventilatory Support Measures in Critically Ill Patients.

Authors:  Shadi Ziaie; Hamidreza Jamaati; Mannan Hajimahmoodi; Seyyed Mohammadreza Hashemian; Fanak Fahimi; Behrooz Farzanegan; Ghazaleh Moghaddam; Golnar Radmand; Behzad Vahdani; Seyed Alireza Nadji; Sarah Mousavi; Hadi Hamishehkar; Mojtaba Mojtahedzadeh
Journal:  Iran J Pharm Res       Date:  2011       Impact factor: 1.696

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.